Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumors That Overexpress HER2 (HER2 Positive) × Immunoglobulin G × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors That Overexpress HER2 (HER2 Positive) 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Mesothelioma, Malignant 1 Cervical Adenocarcinoma 1 Carcinoma, Neuroendocrine 1 Carcinoma, Merkel Cell 1 Adenoma, Islet Cell 1 Adenocarcinoma, Mucinous 1

Interventions

Immunoglobulin G 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02286219 2017-09-18

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

Bristol-Myers Squibb

Phase 1 Completed

Other solid neoplasm

Solid Tumors That Overexpress HER2 (HER2 Positive)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡